Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome

Leukemia Research

Volumn 31, Issue 8, 2007, Pages 1097-1105

  Bogdanović, Gordana ^a   Jurišić, Vladimir ^b   Kraguljac, Nada ^c   Mrdjanović, Jasminka ^a   Jakimov, Dimitar ^a   Krtolica, Koviljka ^d   Krajnović, Milena ^d   Magić, Zvonko ^e   Stojiljković, Bratislav ^a   Andrijević, Ljiljana ^a   Srdić, Tatjana ^f   Baltić, Mirjana ^a   Popović, Stevan ^g  

^a Institute of Oncology Sremska Kamenica   (Yugoslavia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e UNIVERSITY OF DEFENCE   (Serbia)

^f INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^g UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Cytogenetic; DNA; Human cell line; Ig and TCR gene rearrangements; Immunophenotype; Methylation status; MGMT; p15; p16

Indexed keywords

CD15 ANTIGEN; CD30 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICROSOMAL AMINOPEPTIDASE; PROTEIN P15; PROTEIN P16; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL GROWTH; CELL LINE; CHROMOSOME 5P; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME DELETION; CYTOCHEMISTRY; CYTOGENETICS; CYTOLOGY; DNA METHYLATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPING; MALE; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROMOTER REGION; CASE REPORT; CELL CULTURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; T LYMPHOCYTE RECEPTOR GENE; TUMOR SUPPRESSOR GENE;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENES, P16; GENES, T-CELL RECEPTOR; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 34249939084     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.01.012     Document Type: Article

References (50)

1. Stefan F., and Hagop M.K. Chronic leukemias: section 3: myelodisplastic syndromes. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles & practice of oncology (electronic version CD). 7th ed. (2005), Lippincott Williams & Wilkins, Philadelphia [chapter 43: section 3]
2. Lasky J, Sakamoto KM. Topics in pediatric leukemia-myelodisplastic and myeloproliferative disorders of childhood. Medscape Gen Med 2005;7(1):1-6. http://www.medscape.com/viewarticle/498645, posted 3/14/2005. Print April 28, 2005.
3. Delforge M. Understanding the pathogenesis of myelodysplastic syndromes. Hematol J 4 (2003) 303-309
4. INK4b, HIC1, CDH1, and ER is frequent in myelodyspalstic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76 (2006) 23-32
5. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
6. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
7. Bennett J.M., and Komrokji R.S. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 10 Suppl 1 (2005) 258-269
8. Drexler H.G. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leukemia Res 24 (1999) 109-115
9. Nagai M., Fujita M., Ikeda T., Ohmori M., Kuwabara H., Yamaoka G., et al. Alterations of p53 and Rb genes in a novel human GM-CSF-dependent myeloid cell line (OHN-GM) established from therapy-related leukemia. Br J Haematol 98 (1997) 392-398
10. Klobusicka M., Kusenda J., and Babusikova O. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis. Neoplasma 52 (2005) 211-218
11. Rothe G., and Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 10 (1996) 877-895
12. In: Mittelman F. (Ed). An International System for Human Cytogenetic Nomenclature (1995), Karger, Basel
13. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning. A laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press, New York
14. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
15. Esteller M., Toyota M., Sanchez-Cespedes M., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60 (2000) 2368-2371
16. Grunau C., Clark S.J., and Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 29 (2001) E65-E75
17. Segal H.G., Jorgensen T., Masih S.A., and Braylan C.R. Optimal primer selection for clonality assessment by polymerase chain reaction analysis. I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type. Hum Pathol 25 (1994) 1269-1275
18. Belzen van N., Hupkes E.P., Doekharan D., Hoogeveen-Westerveld M., Dorssers J.C.L., and van't Veer B.M. Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodkin's lymphoma. Leukemia 11 (1997) 1742-1752
19. Whittaker S. T-cell receptor gene analysis in cutaneous T-cell lymphomas. Clin Exp Dermatol 2 (1996) 81-87
20. Slack N.D., McCarthy, Wiedemann M.L., and Sloane P.J. Evaluation of sensitivity, specificity, and reproducibility of an optimized method for detecting clonal rearrangements of immunoglobulin and T-cell receptor genes in formalin-fixed, paraffin-embedded sections. Diagnost Mol Pathol 2 (1993) 223-232
21. Drexler H.G., and Matsuo Y. Guidelines for the characterization and publication of human malignant hematopoietic cell lines. Leukemia 13 (1999) 835-842
22. Béné M.-C., Bernier M., Casasnovas R.O., Castoldi G., Doekharan D., and Van Der Holt B. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 113 (2001) 37-45
23. Klobusicka M. Reliability and limitations of cytochemistry in diagnosis of acute myeloid leukemia. Neoplasma 47 (2000) 329-334
24. Lepelley P., Preudhomme C., Sartiaux C., Ghevaert C., Lai J.L., Iaru T., et al. Immunological detection of myeloperoxidase in poorly differentiated acute leukemias. Eur J Haematol 50 (1993) 155-159
25. Van Der Schoot C.E., Daams G.M., Pinkster J., Vet R., and Von Dem Borne A.E.G. Monoclonal antibodies against myeloperoxidase are valuable immunological reagents for the diagnosis of acute myeloid leukemia. Br J Haematol 74 (1990) 173-178
26. Matsuo T., Kuriyama K., Miyazaki Y., Yoshida S., Tomonaga M., Emi N., et al. Japan Adult Leukemia Study Group. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. Leukemia 17 (2003) 1538-1543
27. Chiarle R., Podda A., Prolla G., Gong J., Thorbecke G.J., and Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 90 (1999) 157-164
28. Jurišić V., Bogunović M., Čolović N., and Čolović M. Indolent course of the cutaneous Hodgkin's disease. J Cutan Pathol 32 (2005) 176-178
29. Masuya M., Kita K., Shimizu N., Ohishi K., Katayama N., Sekine T., et al. Biologic characteristics of acute leukemia after myelodysplastic syndrome. Blood 81 (1993) 3388-3394
30. Di Noto R., Luciano L., Lo Pardo C., et al. JURL-MK1 (c-kit (high)/CD30-/CD40-) and JURL-MK2 (c-kit (low)/CD30+/CD40+) cell lines: 'two-sided' model for investigating leukemic megakaryocytopoiesis. Leukemia 11 (1997) 1554-1564
31. Brown G., Drayson M.T., Durham J., et al. HL60 cells halted in G1 or S phase differentiate normally. Exp Cell Res 281 (2002) 28-38
32. Hofman W.-K., Lubbert M., Hoelzer D., and Koffler H.P. Myelodysplastic syndromes. Hematol J 5 (2004) 1-8
33. Mecucci C. Molecular features of primary MDS with cytogenetic changes. Leukemia Res 22 (1998) 293-302
34. Nishino H.T., and Chang C.-C. Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. Arch Pathol Lab Med 129 (2005) 1299-1310
35. 6-methylguanine-DNA-methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol 131 (2005) 364-370
36. Ma X., Yang Q., Wilson K.T., Kundu N., Meltzer S.J., and Fulton A.M. Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Res 6 (2004) 316-321
37. Momparler M.A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1 (1995) 686-692
38. Momparler R., and Bovenzi V. DNA methylation and cancer. J Cell Physiol 183 (2000) 145-154
39. 6-methylguanine-DNA methyltransferase expression during immortalization of cloned human fibroblasts. Carcinogenesis 17 (1996) 219-224
40. 6-mehtylguanine DNA methyltransferase (MGMT) CpG islands is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17 (1997) 5612-5619
41. 6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Mol Carcinog 24 (1999) 85-89
42. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12 (1998) 845-859
43. Quesnel B. Inhibitors of cyclins/CDK of the 9p21 chromosomal region and malignant hemopathies. Bull Cancer 85 (1998) 747-754
44. INK4b is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17 (2003) 1813-1819
45. INK4b gene methylation in myelodysplastic syndromes. Leukemia 17 (2003) 1903-1904
46. Lubbert M. Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes?. Leukemia 17 (2003) 1762-1764
47. Velicescu M., Weisenberger D.J., Gonzales F.A., Tsai Yvonne C., Nguyen Carvell T., and Jones Peter A. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 62 (2002) 2378-2384
48. Laird P.W. The power and promise of DNA methylation markers. Nat Rev Cancer 3 (2003) 253-266
49. Grudeva-Popova J. New options in the treatment of myelodysplastic syndrome. J Buon 10 (2005) 35-42
50. Daskalakis M., Nguyen Tudung T., Nguyen C., Guldberg P., Kohler G., and Wijermans P. Demethylation of a hypermethylated p15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100 (2002) 2957-2964